Evidence map›Paper›PMID 18198129›Full record

ArticleBiochemical and biophysical research communications2008

Tac-beta1 inhibits FAK activation and Src signaling.

Allison L Berrier, Christopher W Jones, Susan E LaFlamme

Abstract read
In one paragraph

Article in Biochemical and biophysical research communications, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Allison L BerrierCenter for Cell Biology and Cancer Research, Albany Medical Center, 47 New Scotland Avenue, Albany, NY 12208, USA.
Christopher W Jones
Susan E LaFlamme
Albany Medical Center Hospital · US

Funding

INTEGRIN INTRACELLULAR FUNCTIONR01GM051540 · NIGMS · ALBANY MEDICAL COLLEGE · PI LAFLAMME, SUSAN · 1994 to 2018
$4.9M
Intramural NIH HHS NIH0012988006NIGMS NIH HHS GM51540NIGMS NIH HHS R01 GM051540
6 · The paper itself

Abstract

The binding of integrins to extracellular matrix triggers signals that promote cell spreading. We previously demonstrated that expression of the integrin beta1 cytoplasmic domain in the context of a chimeric transmembrane receptor with the Tac subunit of the interleukin-2 receptor (Tac-beta1) inhibits cell spreading. To study the mechanism whereby Tac-beta1 inhibits cell spreading, we examined the effect of Tac-beta1 on early signaling events following integrin engagement namely FAK and Src signaling. We infected primary fibroblasts with adenoviruses expressing Tac or Tac-beta1 and found that Tac-beta1 prevented FAK activation by inhibiting the phosphorylation of FAK at Tyr-397. In contrast, Src activation was maintained, as phosphorylation of Src at Tyr-419 and Tyr-530 were not responsive to expression of Tac-beta1. Importantly, adhesion-induced tyrosine phosphorylation of the Src substrates p130Cas and paxillin was inhibited, indicating that Src signaling was blocked by Tac-beta1. These Src-dependent signaling events were found to require FAK signaling. Our results suggest that Tac-beta1 inhibits cell spreading, at least in part, by preventing the phosphorylation of FAK at Tyr-397 and the assembly of signaling complexes necessary for phosphorylation of p130Cas and other downstream effectors.

Indexed as

Signal TransductionCell AdhesionCells, CulturedCrk-Associated Substrate ProteinEnzyme ActivationFocal Adhesion Kinase 1HumansPaxillinPhosphotyrosineProtein SubunitsReceptors, Interleukin-2src-Family KinasesCrk-Associated Substrate ProteinFocal Adhesion Kinase 1PaxillinPhosphotyrosineProtein SubunitsReceptors, Interleukin-2src-Family Kinases

Identifiers

PMID18198129
PMCPMC2587174
OpenAlexW2036985695

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.